You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 10,583,208


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,583,208
Title:Methods for making ultrasound contrast agents
Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Inventor(s): Robinson; Simon P. (Stow, MA), Siegler; Robert W. (Chelmsford, MA), Nguyen; Nhung Tuyet (Westford, MA), Onthank; David C. (Groton, MA), Anklekar; Tarakeshwar Vishwanath (Billerica, MA), Van Kirk; Charles Chester (Beverly, MA)
Assignee: Lantheus Medical Imaging, Inc. (North Billerica, MA)
Application Number:16/264,176
Patent Claims: 1. A method of ultrasound contrast imaging a subject comprising (a) combining an aqueous solvent with a phospholipid solution to form a phospholipid suspension, and activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE, and propylene glycol, the MPEG5000-DPPE selected as having a combined calcium and magnesium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a combined calcium and magnesium concentration of less than 0.7 ppm, (b) administering the lipid-encapsulated gas microspheres to a subject, and (c) obtaining an ultrasound image of the subject.

2. The method of claim 1, wherein DPPA, DPPC and MPEG5000-DPPE are present in molar percentages of 5-15%, 77-90% and 5-15%, respectively.

3. The method of claim 1, wherein DPPA, DPPC and MPEG5000-DPPE are present in a % mole ratio of about 10 to 82 to 8.

4. The method of claim 1, wherein the perfluorocarbon gas is perfluoropropane gas.

5. The method of claim 1, wherein the combined calcium and magnesium concentration of DPPA is less than 780 ppm, the combined calcium and magnesium concentration of DPPC is less than 90 ppm, and the combined calcium and magnesium concentration of propylene glycol is less than 0.7 ppm.

6. The method of claim 1, wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE and propylene glycol, and the aqueous solvent comprises water, propylene glycol and glycerol, and wherein the phospholipid suspension comprises DPPA, DPPC, MPEG5000-DPPE, propylene glycol, water and glycerol.

7. The method of claim 6, wherein water, glycerol and propylene glycol are present in a ratio of about 8:1:1 in the phospholipid suspension.

8. The method of claim 6, wherein the aqueous solvent further comprises one or more salts.

9. The method of claim 6, wherein the aqueous solvent further comprises one or more buffers.

10. A method of ultrasound contrast imaging a subject comprising (a) combining an aqueous solvent with a phospholipid solution to form a phospholipid suspension, and activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid suspension is formed under a methanol and toluene free condition and a methyl-t-butyl ether free condition, the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE, and propylene glycol, the MPEG5000-DPPE having a combined calcium and magnesium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a combined calcium and magnesium concentration of less than 0.7 ppm, (b) administering the lipid-encapsulated gas microspheres to a subject, and (c) obtaining an ultrasound image of the subject.

11. The method of claim 10, wherein DPPA, DPPC and MPEG5000-DPPE are present in molar percentages of about 5-15%, 77-90% and 5-15%, respectively.

12. The method of claim 10, wherein DPPA, DPPC and MPEG5000-DPPE are present in a % mole ratio of about 10 to 82 to 8.

13. The method of claim 10, wherein the perfluorocarbon gas is perfluoropropane gas.

14. The method of claim 10, wherein the combined calcium and magnesium concentration of DPPA is less than 780 ppm, the combined calcium and magnesium concentration of DPPC is less than 90 ppm, and the combined calcium and magnesium concentration of propylene glycol is less than 0.7 ppm.

15. The method of claim 10, wherein the phospholipid solution comprises DPPA, DPPC, MPEG5000-DPPE and propylene glycol, and the aqueous solvent comprises water, propylene glycol and glycerol, and wherein the phospholipid suspension comprises DPPA, DPPC, MPEG5000-DPPE, propylene glycol, water and glycerol.

16. The method of claim 15, wherein water, glycerol and propylene glycol are present in a ratio of about 8:1:1 in the phospholipid suspension.

17. The method of claim 15, wherein the aqueous solvent further comprises one or more salts.

18. The method of claim 15, wherein the aqueous solvent further comprises one or more buffers.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.